Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 2, 2007

View Archived Issues

Recent Dainippon Sumitomo patent discloses novel treatment option for glaucoma

New therapeutic agents for neurological disorders reported in recent patent literature

Recent patents impart novel agents for treating hematological disorders

Cetuximab in gastrointestinal cancers: snapshots of clinical trials

Novel andrographolide analogue DRF-3173 decreases body weight in hyperlipidemic mice

Australian organizations establish cooperative cancer research center

PBI-1393 for cervical cancer completes preclinical toxicology studies

NovoLog approved for pregnancy Category B rating

End-of-phase II meeting for Diamyd

FDA awards orphan drug status to Gestiva for prevention of preterm birth

DSMB stops phase III trial of tesmilifene in advanced breast cancer

AstraZeneca and Palatin collaborate in obesity

Oral azacitidine cleared to begin phase I study

Argenta and AstraZeneca collaborate on bronchodilators for COPD

Phase II study of Ushercell for HIV prevention halted early

Cellzome research program with OrthoMcNeil extended

FDA accepts IND for phase III study of Glypromate

Enrollment target reached in phase II study of MD-05 in dental implantology

Systemic small molecule Hedgehog antagonist begins phase I testing

Novel glycine reuptake inhibitor may be useful to treat alcoholism

Santhera brings forward timelines for idebenone development in Friedreich's ataxia

ATG-3 completes phase I study for wet AMD

FDA Advisory Committee date set for orBec review in GI GVHD

Molecularly targeted anti-EGFR antibody eradicates NSCLC tumors in mice

New phase I/II trial explores AGS-005 in B-cell CLL

GX15-070 begins new trials in NSCLC and mantle cell lymphoma

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...